PeptImmune, Inc.: Series D $8.2M

PeptImmune Inc. (Cambridge, MA) a clinical stage biotechnology company utilizing novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders such as pemphigus vulgaris and multiple sclerosis has closed on the first $8.2M traunche of a Series D financing. Participants include New Enterprise Associates, MPM Capital, Hunt Ventures, Boston Medical Ventures and Silicon Valley Bank Capital.

Proprius Pharma, Inc.: Series A $11M

Proprius Pharmaceuticals (San Diego, CA) a drug developer focused on rheumatology and autoimmune diseases, has raised $11M in Series A funding led by Atlas Venture and joined by Forward Ventures, CDIB BioScience Venture Management along with return backers Fog City Fund and Windamere Venture Partners.